β-tubulinⅢ在宣威非小細(xì)胞肺癌中的表達(dá)與紫杉醇敏感性研究
發(fā)布時(shí)間：2018-08-05 12:44
【摘要】：[研究背景和目的]肺癌的發(fā)病率在我國惡性腫瘤中占首位,非小細(xì)胞肺癌(NSCLC)占到肺癌80%左右,近年來其發(fā)病率有增長(zhǎng)趨勢(shì)。化療是治療中晚期NSCLC主要手段,但化療客觀有效率僅21%左右,甚至更低。已有研究發(fā)現(xiàn)β-tubulinⅢ基因定位在6p21. 3,含有4個(gè)外顯子,而第4個(gè)外顯子是最容易發(fā)生突變的結(jié)合位點(diǎn),其基因突變可改變微管穩(wěn)定性使紫杉醇、長(zhǎng)春瑞濱等藥物與結(jié)合位點(diǎn)作用降低,導(dǎo)致其療效降低甚至無效。因此,探索用于確定云南宣威敏感人群、選擇適宜治療對(duì)象、減少紫杉醇類藥物耐藥的發(fā)生是目前肺癌化學(xué)治療亟待解決的一大問題。目前國內(nèi)外不同研究機(jī)構(gòu)報(bào)道的“腫瘤組織β-tubulinⅢ的表達(dá)與紫杉醇敏感性的關(guān)系”結(jié)果差異較大,而這種差異是否與研究目標(biāo)人群的地域性差異有關(guān)目前尚不清楚。雖然我國北京、上海、廣州等個(gè)別地區(qū)進(jìn)行了部分化療藥物療效相關(guān)基因的檢測(cè)研究,而這些研究機(jī)構(gòu)大多局限于為當(dāng)?shù)胤伟┗颊叩臋z測(cè),且其與肺癌臨床療效的關(guān)系報(bào)道結(jié)果差異較大。本課題主要通過免疫組化法和Western blot檢測(cè)β-tubulinⅢ蛋白在宣威肺腺癌的表達(dá),同時(shí)通過MTT分析β-tubulinⅢ蛋白的表達(dá)對(duì)紫杉醇類藥物敏感性的影響,探索紫杉醇類藥物耐藥的靶點(diǎn),從而為臨床合理使用紫杉醇類藥物提供參考依據(jù),提出符合云南宣威地區(qū)肺癌的“個(gè)體化”綜合治療方案,對(duì)提高云南宣威地區(qū)肺癌的臨床療效無疑具有重要的社會(huì)價(jià)值和科學(xué)意義。[研究方法]1.分析β-tubulinⅢ在宣威肺腺癌細(xì)胞株與肺腺癌A549細(xì)胞株中的表達(dá)差異(1)采用免疫組織化學(xué)法檢測(cè)宣威肺腺癌與肺腺癌A549中β-tubulinⅢ的表達(dá)。(2)在200倍光學(xué)顯微鏡下選取5個(gè)不同區(qū)域計(jì)算β-tubulinⅢ在宣威肺腺癌與肺腺癌A549中表達(dá)的陽性細(xì)胞數(shù)。(3)通過Western blot檢測(cè)宣威腺肺癌與肺腺癌A549中β-tubulinⅢ蛋白的差異性表達(dá)2.分析β-tubulinⅢ在宣威肺腺癌細(xì)胞株與肺腺癌A549細(xì)胞株中的表達(dá)對(duì)紫杉醇敏感性的影響通過MTT法檢測(cè)宣威肺腺癌與肺腺癌A549對(duì)紫杉醇不同濃度隨時(shí)間遷移其細(xì)胞生物活性的影響。3.統(tǒng)計(jì)學(xué)方法采用SPSS 17.0統(tǒng)計(jì)軟件進(jìn)行數(shù)據(jù)分析,進(jìn)行兩組間的均數(shù)比較采用單因素方差分析及獨(dú)立樣本t檢驗(yàn),P0.05為差異有統(tǒng)計(jì)學(xué)意義。[結(jié)果]1.在免疫組化實(shí)驗(yàn)中:β-tubulinⅢ微管蛋白在宣威肺腺癌細(xì)胞株中的平均表達(dá)率為95%,而β-tubulinⅢ微管蛋白在肺腺癌A549細(xì)胞株中的表達(dá)率為86%。2.在Western blot實(shí)驗(yàn)中:通過Image J分析β-tubulinⅢ微管蛋白在宣威肺腺癌細(xì)胞株中表達(dá)的平均灰度值為1.196,β-tubulinⅢ微管蛋白在肺腺癌A549細(xì)胞株中表達(dá)的平均灰度值為0.912。3.在MTT試驗(yàn)中,肺腺癌A549細(xì)胞株抑制率隨著紫杉醇濃度的增加而增加,當(dāng)紫杉醇濃度達(dá)25ug/mL時(shí)其平均抑制率為93%,紫杉醇濃度為50ug/mL時(shí)平均抑制率為95%。在同濃度條件下,在24h、48h、72h之間相比較隨時(shí)間的推移其抑制率逐漸增加(如圖2-1所示)。宣威肺腺癌細(xì)胞株抑制率隨著紫杉醇濃度的增加而增加,當(dāng)紫杉醇濃度達(dá)25ug/mL時(shí)其平均抑制率為52%,紫杉醇濃度為50ug/mL時(shí)平均抑制率為90%。在同濃度條件下,在24h、48h、72h之間相比較隨時(shí)間的推移其抑制率逐漸增加(如圖2-2所示)。在同時(shí)間同濃度調(diào)件下,紫杉醇對(duì)肺腺癌A549細(xì)胞株的平均抑制率高于宣威肺腺癌細(xì)胞株(如圖2-3至圖2-5所示)。[結(jié)論]1.β-tubulinⅢ微管蛋白在宣威肺腺癌中高表達(dá),可能存在地域性差異。2.在β-tubulinⅢ微管蛋白高表達(dá)的宣威肺腺癌中,對(duì)紫杉醇表現(xiàn)出了耐藥性。3.β-tubulinⅢ微管蛋白表達(dá)水平與宣威肺腺癌對(duì)紫杉醇敏感性密切相關(guān),可作為一種以紫杉醇為基礎(chǔ)化療藥物的療效預(yù)測(cè)因子。
[Abstract]:[background and objective] the incidence of lung cancer is the first in China's malignant tumor. Non small cell lung cancer (NSCLC) accounts for about 80% of lung cancer. In recent years, the incidence of lung cancer has been increasing. Chemotherapy is the main method for the treatment of middle and late NSCLC, but the objective and effective rate of chemotherapy is only about 21% and even lower. The study found that the gene of beta -tubulin III is located in 6p 21.3, there are 4 exons, and fourth exons are the most likely mutation binding sites. The mutation of the gene can change the stability of microtubules to reduce the effect of taxol and Changchun Rui litbin and other drugs and binding sites, leading to the reduction of the efficacy and even ineffectiveness. Therefore, the exploration is used to determine the sensitive population of Yunnan Xuanwei, and to select the suitable treatment target. The occurrence of drug resistance of fewer paclitaxel is a major problem to be solved urgently at present. The results of the relationship between the expression of beta -tubulin III in tumor tissue and the sensitivity of taxol in different research institutions at home and abroad differ greatly, and whether this difference is related to the regional difference of the target population is still concerned. It is not clear. Although some regions of China, such as Beijing, Shanghai and Guangzhou, have carried out the detection and study of some genes related to the therapeutic effect of chemotherapeutic drugs, most of these research institutions are limited to the detection of local lung cancer patients, and their relationship with the clinical efficacy of lung cancer is very different. This subject is mainly through immunohistochemical method and Western blot The expression of beta -tubulin III protein in the lung adenocarcinoma of Xuanwei was detected, and the effect of the expression of beta -tubulin III protein on the sensitivity of taxol drugs was analyzed by MTT, and the target of taxol drug resistance was explored, thus providing a reference for the rational use of taxol drugs in clinical practice, and the individualization of lung cancer in Xuanwei area of Yunnan was proposed. "The comprehensive treatment scheme is of great social and scientific significance to improve the clinical efficacy of lung cancer in Xuanwei area of Yunnan. [research method]1. analyses the difference between the expression of beta -tubulin III in the lung adenocarcinoma cell lines of Xuanwei and the A549 cell line of lung adenocarcinoma (1) the detection of beta -tu in Xuanwei lung adenocarcinoma and lung adenocarcinoma A549 by immunohistochemistry Expression of Bulin III. (2) the number of positive cells expressed by beta -tubulin III in Xuanwei lung adenocarcinoma and lung adenocarcinoma A549 was calculated under 200 times optical microscope. (3) the difference of 2. analysis of beta -tubulin III protein in Xuanwei adenocarcinoma and lung adenocarcinoma A549 by Western blot was reached to 2. analysis of beta -tubulin III in Xuanwei lung adenocarcinoma cell line The effect of expression in A549 cell line with lung adenocarcinoma cell line on Taxol sensitivity and the effect of MTT method to detect the effect of different concentrations of paclitaxel on the cell bioactivity of lung adenocarcinoma and lung adenocarcinoma A549,.3. statistical method was used to analyze the data of SPSS 17 statistical software, and the average number of the two groups was compared by single factor. The difference was statistically significant in the difference analysis and independent sample t test. [results]1. in immunohistochemical experiment: the average expression rate of beta -tubulin III microtubulin in Xuanwei lung adenocarcinoma cell line was 95%, while the expression rate of beta -tubulin III microtubulin in A549 cell line of lung adenocarcinoma was 86%.2. in Western blot experiment: Image J score. The average gray value of the expression of beta -tubulin III microtubule in lung adenocarcinoma cell lines was 1.196. The average gray value of the expression of beta -tubulin III microtubulin in A549 cell lines of lung adenocarcinoma was 0.912.3. in the MTT test. The inhibition rate of A549 cell lines in lung adenocarcinoma increased with the increase of paclitaxel concentration. When paclitaxel concentration reached 25ug/mL, the concentration of paclitaxel was 25ug/mL The average inhibitory rate was 93% and the average inhibitory rate of paclitaxel was 50ug/mL at the same concentration of 95%. at the same concentration. The inhibition rate of 24h, 48h and 72h increased gradually with time (as shown in Figure 2-1). The inhibitory rate of the lung adenocarcinoma cell line of Xuanwei increased with the increase of paclitaxel concentration, and the average of paclitaxel concentration reached 25ug/mL. The inhibition rate was 52% and the average inhibitory rate of paclitaxel concentration was 50ug/mL was 90%. at the same concentration. The inhibition rate of 24h, 48h, 72h was gradually increased with time (as shown in Figure 2-2). The average inhibition rate of paclitaxel to lung adenocarcinoma cell line in the same time same concentration was higher than that of Xuanwei lung adenocarcinoma cell line (G. 2- (3 to 2-5) [Conclusion] [conclusion]1. beta -tubulin III microtubulin is highly expressed in Xuanwei lung adenocarcinoma, and there may be regional difference in.2. in the high expression of beta -tubulin III microtubulin in lung adenocarcinoma. The expression of.3. beta -tubulin III microtubulin resistance to paclitaxel is closely related to the sensitivity of Xuanwei lung adenocarcinoma to Taxol sensitivity. It can be used as a predictive factor for the efficacy of paclitaxel based chemotherapy drugs.
【學(xué)位授予單位】：昆明醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R734.2
[Abstract]:[background and objective] the incidence of lung cancer is the first in China's malignant tumor. Non small cell lung cancer (NSCLC) accounts for about 80% of lung cancer. In recent years, the incidence of lung cancer has been increasing. Chemotherapy is the main method for the treatment of middle and late NSCLC, but the objective and effective rate of chemotherapy is only about 21% and even lower. The study found that the gene of beta -tubulin III is located in 6p 21.3, there are 4 exons, and fourth exons are the most likely mutation binding sites. The mutation of the gene can change the stability of microtubules to reduce the effect of taxol and Changchun Rui litbin and other drugs and binding sites, leading to the reduction of the efficacy and even ineffectiveness. Therefore, the exploration is used to determine the sensitive population of Yunnan Xuanwei, and to select the suitable treatment target. The occurrence of drug resistance of fewer paclitaxel is a major problem to be solved urgently at present. The results of the relationship between the expression of beta -tubulin III in tumor tissue and the sensitivity of taxol in different research institutions at home and abroad differ greatly, and whether this difference is related to the regional difference of the target population is still concerned. It is not clear. Although some regions of China, such as Beijing, Shanghai and Guangzhou, have carried out the detection and study of some genes related to the therapeutic effect of chemotherapeutic drugs, most of these research institutions are limited to the detection of local lung cancer patients, and their relationship with the clinical efficacy of lung cancer is very different. This subject is mainly through immunohistochemical method and Western blot The expression of beta -tubulin III protein in the lung adenocarcinoma of Xuanwei was detected, and the effect of the expression of beta -tubulin III protein on the sensitivity of taxol drugs was analyzed by MTT, and the target of taxol drug resistance was explored, thus providing a reference for the rational use of taxol drugs in clinical practice, and the individualization of lung cancer in Xuanwei area of Yunnan was proposed. "The comprehensive treatment scheme is of great social and scientific significance to improve the clinical efficacy of lung cancer in Xuanwei area of Yunnan. [research method]1. analyses the difference between the expression of beta -tubulin III in the lung adenocarcinoma cell lines of Xuanwei and the A549 cell line of lung adenocarcinoma (1) the detection of beta -tu in Xuanwei lung adenocarcinoma and lung adenocarcinoma A549 by immunohistochemistry Expression of Bulin III. (2) the number of positive cells expressed by beta -tubulin III in Xuanwei lung adenocarcinoma and lung adenocarcinoma A549 was calculated under 200 times optical microscope. (3) the difference of 2. analysis of beta -tubulin III protein in Xuanwei adenocarcinoma and lung adenocarcinoma A549 by Western blot was reached to 2. analysis of beta -tubulin III in Xuanwei lung adenocarcinoma cell line The effect of expression in A549 cell line with lung adenocarcinoma cell line on Taxol sensitivity and the effect of MTT method to detect the effect of different concentrations of paclitaxel on the cell bioactivity of lung adenocarcinoma and lung adenocarcinoma A549,.3. statistical method was used to analyze the data of SPSS 17 statistical software, and the average number of the two groups was compared by single factor. The difference was statistically significant in the difference analysis and independent sample t test. [results]1. in immunohistochemical experiment: the average expression rate of beta -tubulin III microtubulin in Xuanwei lung adenocarcinoma cell line was 95%, while the expression rate of beta -tubulin III microtubulin in A549 cell line of lung adenocarcinoma was 86%.2. in Western blot experiment: Image J score. The average gray value of the expression of beta -tubulin III microtubule in lung adenocarcinoma cell lines was 1.196. The average gray value of the expression of beta -tubulin III microtubulin in A549 cell lines of lung adenocarcinoma was 0.912.3. in the MTT test. The inhibition rate of A549 cell lines in lung adenocarcinoma increased with the increase of paclitaxel concentration. When paclitaxel concentration reached 25ug/mL, the concentration of paclitaxel was 25ug/mL The average inhibitory rate was 93% and the average inhibitory rate of paclitaxel was 50ug/mL at the same concentration of 95%. at the same concentration. The inhibition rate of 24h, 48h and 72h increased gradually with time (as shown in Figure 2-1). The inhibitory rate of the lung adenocarcinoma cell line of Xuanwei increased with the increase of paclitaxel concentration, and the average of paclitaxel concentration reached 25ug/mL. The inhibition rate was 52% and the average inhibitory rate of paclitaxel concentration was 50ug/mL was 90%. at the same concentration. The inhibition rate of 24h, 48h, 72h was gradually increased with time (as shown in Figure 2-2). The average inhibition rate of paclitaxel to lung adenocarcinoma cell line in the same time same concentration was higher than that of Xuanwei lung adenocarcinoma cell line (G. 2- (3 to 2-5) [Conclusion] [conclusion]1. beta -tubulin III microtubulin is highly expressed in Xuanwei lung adenocarcinoma, and there may be regional difference in.2. in the high expression of beta -tubulin III microtubulin in lung adenocarcinoma. The expression of.3. beta -tubulin III microtubulin resistance to paclitaxel is closely related to the sensitivity of Xuanwei lung adenocarcinoma to Taxol sensitivity. It can be used as a predictive factor for the efficacy of paclitaxel based chemotherapy drugs.
【學(xué)位授予單位】：昆明醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R734.2
【參考文獻(xiàn)】
相關(guān)期刊論文 前8條
1 梁英平;劉娟妮;白國棟;廖和和;賀艷鋒;楊學(xué)超;;ERCC1、β-Tubulin Ⅲ在非小細(xì)胞肺癌中的表達(dá)及其與肺癌預(yù)后相關(guān)性研究[J];陜西醫(yī)學(xué)雜志;2015年07期
2 戴宏宇;李蘇宜;馬國棟;萬明月;徐玲;夏春偉;權(quán)琳;王毅;陳文萍;;7種β-微管蛋白同型在非小細(xì)胞肺癌中的表達(dá)及其和紫杉類藥物敏感性的研究[J];臨床肺科雜志;2015年03期
3 李正良;;EGFR-TKI治療非小細(xì)胞肺癌后繼發(fā)耐藥的治療進(jìn)展[J];中國腫瘤外科雜志;2015年01期
4 李鵬，
本文編號(hào)：2165835
本文鏈接：http://sikaile.net/yixuelunwen/zlx/2165835.html
最近更新
教材專著
